GO FUND IT NOW

WASHINGTON UNIVERSITY

Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer

Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer is a funding opportunity from WASHINGTON UNIVERSITY, up to 653623, closing August 31, 2027.

Funder
WASHINGTON UNIVERSITY
Funding
653623
Deadline
Aug 31, 2027
(397d left)

Overview

Project Summary/Abstract Triple negative breast cancer (TNBC) is aggressive and a large percentage of patients develop metastatic disease. Disseminated tumor cells (DTCs) found in the bone marrow (BM) of TNBC patients may be the intermediaries of the metastatic process. Data from our lab as well as others suggest that…

Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer | Go Fund It Now